Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Moser, T; Waldispuehl-Geigl, J; Belic, J; Weber, S; Zhou, Q; Hasenleithner, SO; Graf, R; Terzic, JA; Posch, F; Sill, H; Lax, S; Kashofer, K; Hoefler, G; Schoellnast, H; Heitzer, E; Geigl, JB; Bauernhofer, T; Speicher, MR.
On-treatment measurements of circulating tumor DNA during FOLFOX therapy in patients with colorectal cancer.
NPJ Precis Oncol. 2020; 4(1):30
Doi: 10.1038/s41698-020-00134-3
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Bauernhofer Thomas
- Moser Tina
- Speicher Michael
- Co-authors Med Uni Graz
- Belic Jelena
- Geigl Jochen Bernd
- Graf Ricarda
- Hammer Sabrina
- Hasenleithner Samantha
- Heitzer Ellen
- Höfler Gerald
- Kashofer Karl
- Posch Florian
- Schoellnast Helmut
- Sill Heinz
- Spiegelberg Jasmin Alija
- Waldispühl-Geigl Julie
- Zhou Qing
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- We addressed a significant unknown feature of circulating tumor DNA (ctDNA), i.e., how ctDNA levels change during chemotherapy, by serially monitoring ctDNA in patients with colorectal cancer during the 48-h application of FOLFOX. Surprisingly, we did not observe a spike in ctDNA as a sign of a responsive tumor, but instead ctDNA levels initially decreased and remained low in patients with stable disease or partial response. Our observations reveal further insights into cell destruction during chemotherapy with important implications for the management of patients.